FIG. 3.

Performances of AAV2 vectors with AAV1 epitopes in muscle. AAV-CMV-human factor IX vectors based on AAV2 with AAV1 epitopes were purified by CsCl gradient centrifugation and administered intramuscularly to CD4-knockout mice at a dose of 10¹¹ viral genomes per mouse. Blood from mice was drawn at 6 weeks post-vector administration. The expression levels of human factor IX (hFIX) in mouse plasma were measured by ELISA. Each group consists of four mice. AAV1 and AAV2 vectors with the same transgene were used as controls.